grant
Impact of TNF on Oncolytic Virotherapy
Organization UNIVERSITY OF NEW MEXICO HEALTH SCIS CTRLocation ALBUQUERQUE, UNITED STATESPosted 1 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025(TNF)-αAddressAntibodiesApoptosisApoptosis PathwayBindingCD 120b AntigenCD120b AntigensCachectinCell BodyCellsChimera ProteinChimeric ProteinsClinicalDataDevelopmentDiseaseDisorderEdodekin AlfaEnzyme GeneEnzymesFDA approvedFailureFollow-Up StudiesFollowup StudiesFusion ProteinGeneticGoalsHumanIFNIL-12IL12ImmuneImmunesInflammationInterferonsInterleukin-12KnowledgeMacrophage-Derived TNFMediatingMembraneMethodsModelingModern ManMolecularMolecular InteractionMonocyte-Derived TNFMyxoma virusMyxomatosis VirusNKSFNatural Killer Cell Stimulatory FactorNatureOncolyticOncolytic virusesOutcomePD-1 inhibitorsPD-1/PD-L1PD-1/PDL1PD1 inhibitorsPD1-PD-L1PD1/PD-L1PD1/PDL1Pathway interactionsPatientsPlayPoxvirus MyxomatisPre-Clinical ModelPreclinical ModelsProgrammed Cell DeathPropertyReceptors, Tumor Necrosis Factor, Type IIRegulatory PathwayRoleSolid NeoplasmSolid TumorSpecificityT-CellsT-LymphocyteTNFTNF ATNF AlphaTNF geneTNF-R2TNF-RIITNF-αTNFATNFBRTNFR p75TNFR2TNFR80TNFRSF1BTNFRSF1B ReceptorTNFRSF1B geneTNFαTestingTherapeutic antibodiesToxic effectToxicitiesTranslatingTranslationsTreatment EfficacyTumor ImmunityTumor Necrosis FactorTumor Necrosis Factor Beta ReceptorTumor Necrosis Factor Receptor 2Tumor Necrosis Factor Receptor 75Tumor Necrosis Factor Receptor Type 2Tumor Necrosis Factor-alphaViralVirusVirus ReplicationWorkanti programmed cell death protein 1 inhibitoranti-PD-1 inhibitorsanti-PD1 inhibitorsanti-tumor immune responseanti-tumor immunityantitumor immunitycancer immunitycancer infiltrating T cellscancer microenvironmentcancer virotherapyclinical applicabilityclinical applicationclinical effectclinical translationclinically translatabledesigndesigningdevelopmentalimmune clearanceimmune eliminationimmune-mediated adverse eventsimmune-related adverse effectimmune-related adverse eventsimmune-related adverse reactionimprovedin vivoinhibitorintervention efficacymembrane structurenoveloncolytic viral therapeuticoncolytic viral therapyoncolytic virotherapeuticoncolytic virotherapyoncolytic virus therapypathwaypreventpreventingsocial rolesuccesssynergismtherapeutic efficacytherapy efficacythymus derived lymphocytetranslationtumortumor infiltrating T cellstumor microenvironmenttumor necrosis factor receptor superfamily, member 1Bviral multiplicationviral replicationvirus multiplication
Description preview
Project Summary: Oncolytic virotherapy (OV) represents a novel method to treat a variety of solid tumors by
inducing anti-tumor immune responses. While this therapy has been extremely efficacious in a wide variety of
preclinical models, translating these successes into human patients has proven challenging. It has recently
become clear that one of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click